Actavis’ $25 Billion Forest Labs Buy Expands Geographic Reach, Product Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
The merged company will hold blockbuster franchises in CNS, gastroenterology and women’s health, involving generics as well as brands, as well as a large and diversified U.S. sales force and the means to invest more than $1 billion annually in R&D.